接受雄激素剥夺治疗的前列腺癌老年医疗保险受益者阿尔茨海默病风险
校正其他抗癌治疗后,ADT 与 AD 风险无增加相关(SHR 0.98),痴呆风险仅极小(SHR 1.01),ADT 组更可能在进展为 AD 或痴呆前死亡。
要点
- 校正其他抗癌治疗后,ADT 与阿尔茨海默病风险无增加相关(SHR 0.98)。
- ADT 与痴呆风险仅呈极小相关(SHR 1.01),作者认为无实质危害。
- AD 与痴呆风险与 ADT 疗程无关,未见剂量效应。
核心结论
- 这些数据提示,在入组 Medicare 的67岁及以上男性中,ADT 治疗对阿尔茨海默病无危害,对痴呆无实质性危害。
研究设计与样本
- 基于 Medicare 理赔数据库的受益者数据分析,纳入2001至2014年发生前列腺癌的67岁及以上按服务收费受益人。
- 预先设定的生存分析方法为竞争风险回归,评估 ADT 与 AD 及痴呆的未校正和校正风险。
主要发现
- 其中109,815例(8.9%)发生 AD,223,765例(18.8%)发生痴呆,26%至33%未发生任一结局即死亡。
- ADT 接受者与未接受者的 AD 未校正率分别为每1000人年17.0与15.5,全因死亡率分别为每1000人年73.0与51.6。
- ADT 接受者与未接受者的痴呆未校正率分别为38.5与32.9,死亡率分别为60.2与40.4。
- 校正其他抗癌治疗及其他协变量后,ADT 治疗者 AD 风险未增加(SHR 0.98;95%CI 0.97至0.99),痴呆风险仅极小(1%)(SHR 1.01;95%CI 1.01至1.02)。
关键数值与推荐
- ADT 治疗者进展为 AD 前死亡的可能性更高(SHR 1.24;95%CI 1.23至1.24),进展为痴呆前死亡的可能性更高(SHR 1.26;95%CI 1.25至1.26)。
- AD 与痴呆风险与 ADT 疗程无关,即无剂量效应。
- 其他二次分析证实了上述结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To assess the relative risk of Alzheimer's disease (AD) among patients with prostate cancer who received androgen deprivation therapy (ADT), after adjustment for other cancer therapies. Methods Data from demographics, survival, diagnoses codes, procedure codes, and other information about beneficiaries age 67 years or older in the Medicare claims database was assessed to determine the unadjusted and adjusted risks of AD and of dementia from ADT. The prespecified survival analysis method was competing risk regression. Results Of the 1.2 million fee-for-service Medicare beneficiaries who developed prostate cancer in 2001 to 2014, 35% received ADT. Of these, 109,815 (8.9%) and 223,765 (18.8%) developed AD and dementia, respectively, and 26% to 33% died without either outcome. Unadjusted rates of AD and all-cause mortality per 1,000 patient-years were higher among ADT recipients; the unadjusted rates of AD were 17.0 and 15.5 per 1,000 person-years in recipients and nonrecipients, respectively, and the unadjusted rates of all-cause mortality were 73.0 and 51.6 per 1,000 person-years, respectively. The unadjusted rates for dementia in ADT recipients versus nonrecipients were 38.5 and 32.9, respectively, and the unadjusted rates of mortality were 60.2 versus 40.4, respectively. However, after analysis was adjusted for other cancer therapies and other covariates, patients with ADT treatment had no increased risk of AD (subdistribution hazard ratio [SHR], 0.98; 95% CI, 0.97 to 0.99) and had only a miniscule (1%) risk of dementia (SHR, 1.01; 95% CI, 1.01 to 1.02); patients treated with ADT were more likely to die before progression to AD (SHR, 1.24; 95% CI, 1.23 to 1.24) or dementia (SHR, 1.26; 95% CI, 1.25 to 1.26). The risks of AD and dementia were not associated with duration of ADT (ie, no dose effect). Other secondary analyses confirmed these results. Conclusion These data suggest that ADT treatment has no hazard for AD and no meaningful hazard for dementia among men age 67 years or older who are enrolled in Medicare.
引用
- Baik SH, Kury FSP, McDonald CJ, et al. Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer. J Clin Oncol. 2017. PMID: 28841388. doi:10.1200/JCO.2017.72.6109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。